Key result
Direct oral anticoagulants reduced the risk of venous thromboembolism recurrence compared to low molecular weight heparins in cancer patients.
Why the study?
To evaluate the efficacy and safety of different DOACs compared with LMWHs in the treatment of VTE in cancer patients.
Do direct oral anticoagulants (DOACs) reduce recurrent venous thromboembolism compared to low molecular weight heparin (LMWHs) in cancer patients?
Meta-Analysis (n=7,319)
Do direct oral anticoagulants (DOACs) reduce recurrent venous thromboembolism compared to low molecular weight heparin (LMWHs) in cancer patients?
In cancer patients with VTE, DOACs (particularly rivaroxaban) significantly reduce the risk of recurrent VTE and DVT compared to LMWHs, though they may increase the risk of clinically relevant non-major bleeding.
Answers are grounded in this paper and cite their sources.
DOACs reduce recurrent VTE risk versus LMWH in cancer; reinforces first-line preference while leaving optimal agent selection open.
Background: To evaluate the efficacy and safety of different direct oral anticoagulants (DOACs) compared with low molecular weight heparin (LMWHs) in the treatment of venous thromboembolism (VTE) in cancer patients. Methods: Literature was searched in databases including Cochrane Library, EMBASE (Ovid) and MEDLINE (Pubmed). Eligible studies were included and data were collected independently by two reviewers. We conducted a systemic review of the efficacy and safety of DOACs in the treatment of VTE in cancer patients. The odds ratios of different DOACs compared with LMWHs for VTE, DVT, PE recurrences, major bleeding and clinically relevant non-major bleeding (CRNMB) were calculated in meta-analyses and subgroup analyses. Results: A total of 18 articles were eligible for analyses, including 4 randomized controlled trials (RCTs) and 14 retrospective studies. Both RCTs and retrospective studies confirmed that DOACs decreased the risk of VTE recurrence (RCTs: OR, 0.60; 95%CI, 0.45-0.80; retrospective studies: OR, 0.73; 95%CI, 0.59-0.90) and DVT recurrence (RCTs: OR, 0.54; 95%CI, 0.36-0.80; retrospective studies: OR, 0.20; 95%CI, 0.06-0.63), but not PE recurrence or fatal PE in cancer patients. Subgroup analyses revealed an important role of rivaroxaban in decreasing recurrent VTE. Meanwhile, major bleeding events were not increased in the DOAC group, but the risk of CRNMBs were significantly elevated. Subgroup analyses confirmed the role of rivaroxaban in increasing the risk of major bleeding events and CRNMBs. Conclusions: Compared with LMWHs, DOACs, especially rivaroxaban, significantly reduced the risk of VTE and DVT, rather than PE, recurrence in patients with cancer. Although DOACs did not increase the major bleeding events in pooled analysis, rivaroxaban was showed an elevated risk of this adverse effect in subgroup analysis. In addition, the risk of CRNMB events was increased after the application of DOACs including rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Song et al. (2020) conducted a meta-analysis in Venous thromboembolism in cancer patients (n=7,319). Direct oral anticoagulants (DOACs) vs. Low molecular weight heparin (LMWHs) was evaluated on Venous thromboembolism (VTE) recurrence (OR 0.68, 95% CI 0.57-0.8, p=<0.001). Direct oral anticoagulants reduced the risk of venous thromboembolism recurrence compared to low molecular weight heparins in cancer patients.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: